Evidence Snapshot

Estrogen receptor beta

CHEMBL242 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:18Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 12:22 PM KST As of · Sep 14, 2026

ChEMBL ChEMBL 36 CHEMBL242

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Estrogen receptor beta as ChEMBL target CHEMBL242, mapped to UniProt Q92731. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Estrogen receptor beta

SINGLE PROTEIN · Homo sapiens

As of 2026-09-14

ChEMBL target ID

CHEMBL242

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-14

www.ebi.ac.uk

UniProt accession

Q92731

Estrogen receptor beta

UniProt accession via ChEMBL component mapping As of 2026-09-14

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-14

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Estrogen receptor beta matters

As of 2026-09-14

Estrogen receptor beta is reviewed as Estrogen receptor beta (UniProt Q92731); Estrogen receptor beta shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 34 approved drugs, 5139 compounds, and 726 assays, with lead potency reaching pChEMBL 11.0.

Protein context

Estrogen receptor beta

Estrogen receptor beta Sequence length is 530 aa.

Review this target as Estrogen receptor beta, mapped to UniProt Q92731. Sequence length is 530 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q92731 Protein

Disease context

breast cancer

Estrogen receptor beta shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AUS-131, ESTRAMUSTINE PHOSPHATE SODIUM, RALOXIFENE HYDROCHLORIDE.

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include AUS-131, ESTRAMUSTINE PHOSPHATE SODIUM, RALOXIFENE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 3 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 34 approved drugs, 5139 compounds, and 726 assays for this target. The dominant activity type is IC50. CHEMBL135 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL135 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

34 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Estrogen receptor beta matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q92731, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why breast cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5139

Total Compounds

726

Total Assays

Approved Drugs

IC50: 3617.0, KI: 1442.0, EC50: 949.0, KD: 32.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL135	11.0	EC50	Approved
No preferred name CHEMBL2137046	10.8	Ki	—
No preferred name CHEMBL135	10.8	Ki	Approved
No preferred name CHEMBL411	10.7	EC50	Approved
No preferred name CHEMBL1627464	10.6	Ki	—

Approved Drugs

Structure	Compound	First Approval
	ELACESTRANT CHEMBL4297509	2023
	ESTETROL ANHYDROUS CHEMBL1230314	2021
	LASOFOXIFENE CHEMBL328190	2009
	BAZEDOXIFENE CHEMBL46740	2009
	FULVESTRANT CHEMBL1358	2002
	ESTRIOL CHEMBL193482	2000
	MIFEPRISTONE CHEMBL1276308	2000
	RALOXIFENE CHEMBL81	1997
	RALOXIFENE HYDROCHLORIDE CHEMBL1116	1997
	ETHINYL ESTRADIOL CHEMBL691	1982
	ESTRONE CHEMBL1405	1979
	TAMOXIFEN CHEMBL83	1977
	TAMOXIFEN CITRATE CHEMBL786	1977
	ESTRADIOL CHEMBL135	1975
	DIETHYLSTILBESTROL CHEMBL411	1973
	DEMECLOCYCLINE HYDROCHLORIDE CHEMBL1200474	1960
	HEXACHLOROPHENE CHEMBL496	1949

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:18Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 12:22 PM KST As of · Sep 14, 2026

ChEMBL ChEMBL 36 CHEMBL242